Bayer has partnered with Arvinas to develop therapies for cardiovascular, oncological and gynaecological diseases. Under the target-based research alliance, Arvinas will receive $60m as an upfront payment and a direct equity investment from Bayer, as well […]
SMi reports: Invitation from conference co-chair released for the 9th Annual Orphan Drugs & Rare Diseases conference, taking place in London this October In October, attendees will hear various key presentations by leading solution providers, […]
SMi Reports: SMi Group are delighted to announce that registration is open for the 5th Annual Lyophilization USA conference, taking place October 23rd-24th in Boston. Despite being a relatively old process, there is much need […]
SMi reports: Registration is now open for the 3rd annual Ophthalmic Drugs Conference and Focus Day, taking place in London this November The global ophthalmic drug market size is expected to reach a value of […]
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and […]